

BIOCRYST PHARMACEUTICALS INC  
Form SC 13G/A  
February 14, 2017

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**SCHEDULE 13G/A**

**Under the Securities Exchange Act of 1934  
(Amendment No. 1)\***

**BioCryst Pharmaceuticals, Inc.**

(Name of Issuer)

**Common Stock, \$0.01 par value**

(Title of Class of Securities)

**09058V103**

(CUSIP Number)

**December 31, 2016**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 09058V103

- |     |   |  |
|-----|---|--|
| 1.  | Name of Reporting Persons<br>Venrock Healthcare Capital Partners, L.P.              |  |
| 2.  | Check the Appropriate Box if a Member of a Group (See Instructions)                 |  |
|     | (a) <input checked="" type="checkbox"/> (1)   |  |
|     | (b) <input type="checkbox"/> (0)  |  |
| 3.  | SEC Use Only  |  |
| 4.  | Citizenship or Place of Organization<br>Delaware                                    |  |
| 5.  |   | Sole Voting Power<br>0                   |
| 6.  |   | Shared Voting Power<br>7,226,246(2)      |
| 7.  |   | Sole Dispositive Power<br>0              |
| 8.  |   | Shared Dispositive Power<br>7,226,246(2) |
| 9.  | Aggregate Amount Beneficially Owned by Each Reporting Person<br>7,226,246(2)        |  |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) | <input type="checkbox"/> (0)             |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.8%(3)                        |  |
| 12. | Type of Reporting Person (See Instructions)<br>PN                                   |  |

(1) Venrock Healthcare Capital Partners, L.P., VHCP Co-Investment Holdings, LLC, Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management, LLC, VHCP Management II, LLC, Bong Koh and Nimish Shah are members of a group for the purposes of this Schedule 13G/A.

(2) Consists of 976,482 shares owned by Venrock Healthcare Capital Partners, L.P., 178,622 shares owned by VHCP Co-Investment Holdings, LLC, 4,319,726 shares owned by Venrock Healthcare Capital Partners II, L.P. and 1,751,416 shares owned by VHCP Co-Investment Holdings II, LLC.

(3) This percentage is calculated based upon 73,758,320 shares of the Issuer's common stock outstanding as of October 31, 2016, as set forth in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2016.



Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 09058V103

- |     |   |  |
|-----|---|--|
| 1.  | Name of Reporting Persons<br>VHCP Co-Investment Holdings, LLC                       |  |
| 2.  | Check the Appropriate Box if a Member of a Group (See Instructions)                 |  |
|     | (a) <input checked="" type="checkbox"/> (1)   |  |
|     | (b) <input type="checkbox"/> (0)  |  |
| 3.  | SEC Use Only  |  |
| 4.  | Citizenship or Place of Organization<br>Delaware                                    |  |
| 5.  |   | Sole Voting Power<br>0                   |
| 6.  |   | Shared Voting Power<br>7,226,246(2)      |
| 7.  |   | Sole Dispositive Power<br>0              |
| 8.  |   | Shared Dispositive Power<br>7,226,246(2) |
| 9.  | Aggregate Amount Beneficially Owned by Each Reporting Person<br>7,226,246(2)        |  |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) | <input type="checkbox"/> (0)             |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.8%(3)                        |  |
| 12. | Type of Reporting Person (See Instructions)<br>OO                                   |  |

(1) Venrock Healthcare Capital Partners, L.P., VHCP Co-Investment Holdings, LLC, Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management, LLC, VHCP Management II, LLC, Bong Koh and Nimish Shah are members of a group for the purposes of this Schedule 13G/A.

(2) Consists of 976,482 shares owned by Venrock Healthcare Capital Partners, L.P., 178,622 shares owned by VHCP Co-Investment Holdings, LLC, 4,319,726 shares owned by Venrock Healthcare Capital Partners II, L.P. and 1,751,416 shares owned by VHCP Co-Investment Holdings II, LLC.

(3) This percentage is calculated based upon 73,758,320 shares of the Issuer's common stock outstanding as of October 31, 2016, as set forth in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2016.



Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 09058V103

- |     |   |  |
|-----|---|--|
| 1.  | Name of Reporting Persons<br>Venrock Healthcare Capital Partners II, L.P.           |  |
| 2.  | Check the Appropriate Box if a Member of a Group (See Instructions)                 |  |
|     | (a) <input checked="" type="checkbox"/> (1)   |  |
|     | (b) <input type="checkbox"/> (0)  |  |
| 3.  | SEC Use Only  |  |
| 4.  | Citizenship or Place of Organization<br>Delaware                                    |  |
| 5.  |   | Sole Voting Power<br>0                   |
| 6.  |   | Shared Voting Power<br>7,226,246(2)      |
| 7.  |   | Sole Dispositive Power<br>0              |
| 8.  |   | Shared Dispositive Power<br>7,226,246(2) |
| 9.  | Aggregate Amount Beneficially Owned by Each Reporting Person<br>7,226,246(2)        |  |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) | <input type="checkbox"/> (0)             |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.8%(3)                        |  |
| 12. | Type of Reporting Person (See Instructions)<br>PN                                   |  |

(1) Venrock Healthcare Capital Partners, L.P., VHCP Co-Investment Holdings, LLC, Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management, LLC, VHCP Management II, LLC, Bong Koh and Nimish Shah are members of a group for the purposes of this Schedule 13G/A.

(2) Consists of 976,482 shares owned by Venrock Healthcare Capital Partners, L.P., 178,622 shares owned by VHCP Co-Investment Holdings, LLC, 4,319,726 shares owned by Venrock Healthcare Capital Partners II, L.P. and 1,751,416 shares owned by VHCP Co-Investment Holdings II, LLC.

(3) This percentage is calculated based upon 73,758,320 shares of the Issuer's common stock outstanding as of October 31, 2016, as set forth in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2016.



Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 09058V103

- |     |  |
|-----|--|
| 1.  | Name of Reporting Persons<br>VHCP Co-Investment Holdings II, LLC   |
| 2.  | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) <input checked="" type="checkbox"/> (1)<br>(b) <input type="checkbox"/> (0) |
| 3.  | SEC Use Only   |
| 4.  | Citizenship or Place of Organization<br>Delaware   |
| 5.  | Sole Voting Power<br>0   |
| 6.  | Shared Voting Power<br>7,226,246(2)  |
| 7.  | Sole Dispositive Power<br>0  |
| 8.  | Shared Dispositive Power<br>7,226,246(2)   |
| 9.  | Aggregate Amount Beneficially Owned by Each Reporting Person<br>7,226,246(2)   |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/>   |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.8%(3)   |
| 12. | Type of Reporting Person (See Instructions)<br>OO  |

(1) Venrock Healthcare Capital Partners, L.P., VHCP Co-Investment Holdings, LLC, Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management, LLC, VHCP Management II, LLC, Bong Koh and Nimish Shah are members of a group for the purposes of this Schedule 13G/A.

(2) Consists of 976,482 shares owned by Venrock Healthcare Capital Partners, L.P., 178,622 shares owned by VHCP Co-Investment Holdings, LLC, 4,319,726 shares owned by Venrock Healthcare Capital Partners II, L.P. and 1,751,416 shares owned by VHCP Co-Investment Holdings II, LLC.

(3) This percentage is calculated based upon 73,758,320 shares of the Issuer's common stock outstanding as of October 31, 2016, as set forth in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2016.





Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 09058V103

- |     |   |  |
|-----|---|--|
| 1.  | Name of Reporting Persons<br>VHCP Management, LLC                                   |  |
| 2.  | Check the Appropriate Box if a Member of a Group (See Instructions)                 |  |
|     | (a)   | x(1)                                     |
|     | (b)   | o  |
| 3.  | SEC Use Only  |  |
| 4.  | Citizenship or Place of Organization<br>Delaware                                    |  |
| 5.  |   | Sole Voting Power<br>0                   |
| 6.  |   | Shared Voting Power<br>7,226,246(2)      |
| 7.  |   | Sole Dispositive Power<br>0              |
| 8.  |   | Shared Dispositive Power<br>7,226,246(2) |
| 9.  | Aggregate Amount Beneficially Owned by Each Reporting Person<br>7,226,246(2)        |  |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) | o  |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.8%(3)                        |  |
| 12. | Type of Reporting Person (See Instructions)<br>OO                                   |  |

(1) Venrock Healthcare Capital Partners, L.P., VHCP Co-Investment Holdings, LLC, Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management, LLC, VHCP Management II, LLC, Bong Koh and Nimish Shah are members of a group for the purposes of this Schedule 13G/A.

(2) Consists of 976,482 shares owned by Venrock Healthcare Capital Partners, L.P., 178,622 shares owned by VHCP Co-Investment Holdings, LLC, 4,319,726 shares owned by Venrock Healthcare Capital Partners II, L.P. and 1,751,416 shares owned by VHCP Co-Investment Holdings II, LLC.

(3) This percentage is calculated based upon 73,758,320 shares of the Issuer's common stock outstanding as of October 31, 2016, as set forth in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2016.



Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 09058V103

- |     |   |  |
|-----|---|--|
| 1.  | Name of Reporting Persons<br>VHCP Management II, LLC                                |  |
| 2.  | Check the Appropriate Box if a Member of a Group (See Instructions)                 |  |
|     | (a) <input checked="" type="checkbox"/> (1)   |  |
|     | (b) <input type="checkbox"/> (0)  |  |
| 3.  | SEC Use Only  |  |
| 4.  | Citizenship or Place of Organization<br>Delaware                                    |  |
| 5.  |   | Sole Voting Power<br>0                   |
| 6.  |   | Shared Voting Power<br>7,226,246(2)      |
| 7.  |   | Sole Dispositive Power<br>0              |
| 8.  |   | Shared Dispositive Power<br>7,226,246(2) |
| 9.  | Aggregate Amount Beneficially Owned by Each Reporting Person<br>7,226,246(2)        |  |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) | <input type="checkbox"/> (0)             |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.8%(3)                        |  |
| 12. | Type of Reporting Person (See Instructions)<br>OO                                   |  |

(1) Venrock Healthcare Capital Partners, L.P., VHCP Co-Investment Holdings, LLC, Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management, LLC, VHCP Management II, LLC, Bong Koh and Nimish Shah are members of a group for the purposes of this Schedule 13G/A.

(2) Consists of 976,482 shares owned by Venrock Healthcare Capital Partners, L.P., 178,622 shares owned by VHCP Co-Investment Holdings, LLC, 4,319,726 shares owned by Venrock Healthcare Capital Partners II, L.P. and 1,751,416 shares owned by VHCP Co-Investment Holdings II, LLC.

(3) This percentage is calculated based upon 73,758,320 shares of the Issuer's common stock outstanding as of October 31, 2016, as set forth in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2016.



Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 09058V103

- |     |   |  |
|-----|---|--|
| 1.  | Name of Reporting Persons<br>Shah, Nimish   |  |
| 2.  | Check the Appropriate Box if a Member of a Group (See Instructions)                 |  |
|     | (a) <input checked="" type="checkbox"/> (1)   |  |
|     | (b) <input type="checkbox"/> (0)  |  |
| 3.  | SEC Use Only  |  |
| 4.  | Citizenship or Place of Organization<br>United States                               |  |
| 5.  |   | Sole Voting Power<br>0                   |
| 6.  |   | Shared Voting Power<br>7,226,246(2)      |
| 7.  |   | Sole Dispositive Power<br>0              |
| 8.  |   | Shared Dispositive Power<br>7,226,246(2) |
| 9.  | Aggregate Amount Beneficially Owned by Each Reporting Person<br>7,226,246(2)        |  |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) | <input type="checkbox"/> (0)             |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.8%(3)                        |  |
| 12. | Type of Reporting Person (See Instructions)<br>IN                                   |  |

(1) Venrock Healthcare Capital Partners, L.P., VHCP Co-Investment Holdings, LLC, Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management, LLC, VHCP Management II, LLC, Bong Koh and Nimish Shah are members of a group for the purposes of this Schedule 13G/A.

(2) Consists of 976,482 shares owned by Venrock Healthcare Capital Partners, L.P., 178,622 shares owned by VHCP Co-Investment Holdings, LLC, 4,319,726 shares owned by Venrock Healthcare Capital Partners II, L.P. and 1,751,416 shares owned by VHCP Co-Investment Holdings II, LLC.

(3) This percentage is calculated based upon 73,758,320 shares of the Issuer's common stock outstanding as of October 31, 2016, as set forth in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2016.



Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 09058V103

- |     |   |  |
|-----|---|--|
| 1.  | Name of Reporting Persons<br>Koh, Bong  |  |
| 2.  | Check the Appropriate Box if a Member of a Group (See Instructions)                 |  |
|     | (a) <input checked="" type="checkbox"/> (1)   |  |
|     | (b) <input type="checkbox"/> (0)  |  |
| 3.  | SEC Use Only  |  |
| 4.  | Citizenship or Place of Organization<br>United States                               |  |
| 5.  |   | Sole Voting Power<br>0                   |
| 6.  |   | Shared Voting Power<br>7,226,246(2)      |
| 7.  |   | Sole Dispositive Power<br>0              |
| 8.  |   | Shared Dispositive Power<br>7,226,246(2) |
| 9.  | Aggregate Amount Beneficially Owned by Each Reporting Person<br>7,226,246(2)        |  |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) | <input type="checkbox"/> (0)             |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.8%(3)                        |  |
| 12. | Type of Reporting Person (See Instructions)<br>IN                                   |  |

(1) Venrock Healthcare Capital Partners, L.P., VHCP Co-Investment Holdings, LLC, Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management, LLC, VHCP Management II, LLC, Bong Koh and Nimish Shah are members of a group for the purposes of this Schedule 13G/A.

(2) Consists of 976,482 shares owned by Venrock Healthcare Capital Partners, L.P., 178,622 shares owned by VHCP Co-Investment Holdings, LLC, 4,319,726 shares owned by Venrock Healthcare Capital Partners II, L.P. and 1,751,416 shares owned by VHCP Co-Investment Holdings II, LLC.

(3) This percentage is calculated based upon 73,758,320 shares of the Issuer's common stock outstanding as of October 31, 2016, as set forth in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2016.





CUSIP No. 09058V103		
---------------------	--	--

Introductory Note: This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners, L.P., a limited partnership organized under the laws of the State of Delaware ( VHCP I ), VHCP Co-Investment Holdings, LLC, a limited liability company organized under the laws of the State of Delaware ( VHCP Co-Invest I ), Venrock Healthcare Capital Partners II, L.P., a limited partnership organized under the laws of the State of Delaware ( VHCP II ), VHCP Co-Investment Holdings II, LLC, a limited liability company organized under the laws of the State of Delaware ( VHCP Co-Invest II ), VHCP Management, LLC, a limited liability company organized under the laws of the State of Delaware ( VHCP Management ), VHCP Management II, LLC, a limited liability company organized under the laws of the State of Delaware ( VHCP Management II ) and collectively with VHCP I, VHCP Co-Invest I, VHCP II, VHCP Co-Investment II, and VHCP Management, the Venrock Entities ), Bong Koh ( Koh ) and Nimish Shah ( Shah ) in respect of Common Stock of BioCryst Pharmaceuticals, Inc.

**Item 1.**

- (a) Name of Issuer  
BioCryst Pharmaceuticals, Inc.
- (b) Address of Issuer's Principal Executive Offices  
4505 Emperor Boulevard, Suite 200  
  
Durham, NC 27703

**Item 2.**

- (a) Name of Person Filing  
Venrock Healthcare Capital Partners, L.P.  
  
VHCP Co-Investment Holdings, LLC  
  
Venrock Healthcare Capital Partners II, L.P.  
  
VHCP Co-Investment Holdings II, LLC  
  
VHCP Management, LLC  
  
VHCP Management II, LLC  
  
Bong Koh
- (b) Nimish Shah  
Address of Principal Business Office or, if none, Residence  
New York Office: Palo Alto Office: Boston Office:  
530 Fifth Avenue 3340 Hillview Avenue 34 Farnsworth Street  
22nd Floor Palo Alto, CA 94304 3rd Floor  
New York, NY 10036 Boston, MA 02210
- (c) Citizenship  
All entities were organized in Delaware. The individuals are both United States citizens.
- (d) Title of Class of Securities  
Common Stock, \$0.01 par value
- (e) CUSIP Number  
09058V103

**Item 3.**

Not applicable

**If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:**



CUSIP No. 09058V103		
---------------------	--	--

**Item 4. Ownership**

(a) Amount Beneficially Owned as of December 31, 2016:

Venrock Healthcare Capital Partners, L.P.	7,226,246(1)
VHCP Co-Investment Holdings, LLC	7,226,246(1)
Venrock Healthcare Capital Partners II, L.P.	7,226,246(1)
VHCP Co-Investment Holdings II, LLC	7,226,246(1)
VHCP Management, LLC	7,226,246(1)
VHCP Management II, LLC	7,226,246(1)
Bong Koh	7,226,246(1)
Nimish Shah	7,226,246(1)

(b) Percent of Class as of December 31, 2016:

Venrock Healthcare Capital Partners, L.P.	9.8%(2)
VHCP Co-Investment Holdings, LLC	9.8%(2)
Venrock Healthcare Capital Partners II, L.P.	9.8%(2)
VHCP Co-Investment Holdings II, LLC	9.8%(2)
VHCP Management, LLC	9.8%(2)
VHCP Management II, LLC	9.8%(2)
Bong Koh	9.8%(2)
Nimish Shah	9.8%(2)

(c) Number of shares as to which the person has, as of December 31, 2016:

(i) Sole power to vote or to direct the vote

Venrock Healthcare Capital Partners, L.P.	0
VHCP Co-Investment Holdings, LLC	0
Venrock Healthcare Capital Partners II, L.P.	0
VHCP Co-Investment Holdings II, LLC	0
VHCP Management, LLC	0
VHCP Management II, LLC	0
Bong Koh	0
Nimish Shah	0

(ii) Shared power to vote or to direct the vote

Venrock Healthcare Capital Partners, L.P.	7,226,246(1)
VHCP Co-Investment Holdings, LLC	7,226,246(1)
Venrock Healthcare Capital Partners II, L.P.	7,226,246(1)
VHCP Co-Investment Holdings II, LLC	7,226,246(1)
VHCP Management, LLC	7,226,246(1)
VHCP Management II, LLC	7,226,246(1)
Bong Koh	7,226,246(1)
Nimish Shah	7,226,246(1)

(iii) Sole power to dispose or to direct the disposition of

Venrock Healthcare Capital Partners, L.P.	0
VHCP Co-Investment Holdings, LLC	0
Venrock Healthcare Capital Partners II, L.P.	0
VHCP Co-Investment Holdings II, LLC	0
VHCP Management, LLC	0
VHCP Management II, LLC	0
Bong Koh	0
Nimish Shah	0

(iv) Shared power to dispose or to direct the disposition of

Venrock Healthcare Capital Partners, L.P.	7,226,246(1)
VHCP Co-Investment Holdings, LLC	7,226,246(1)
Venrock Healthcare Capital Partners II, L.P.	7,226,246(1)
VHCP Co-Investment Holdings II, LLC	7,226,246(1)
VHCP Management, LLC	7,226,246(1)
VHCP Management II, LLC	7,226,246(1)
Bong Koh	7,226,246(1)
Nimish Shah	7,226,246(1)

(1) These shares are owned directly as follows: 976,482 shares are owned by VHCP I, 178,622 shares are owned by VHCP Co-Invest I, 4,319,726 shares are owned by VHCP II and 1,751,416 shares are owned by VHCP Co-Invest II.

(2) This percentage is calculated based upon 73,758,320 shares of the Issuer's common stock outstanding as of October 31, 2016, as set forth in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2016.

**Item 5. Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

**Item 6. Ownership of More than Five Percent on Behalf of Another Person**

Not Applicable

**Item 7.**

**Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.**

Not Applicable

**Item 8.**

**Identification and Classification of Members of the Group**

Not Applicable

**Item 9.**

**Notice of Dissolution of a Group**

Not Applicable

CUSIP No. 09058V103		
---------------------	--	--

**Item 10.**

**Certification**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

Dated: February 14, 2017

**Venrock Healthcare Capital Partners, L.P.**

By: VHCP Management, LLC,  
its General Partner

By: /s/ David L. Stepp  
Name: David L. Stepp  
Title: Authorized Signatory

**VHCP Co-Investment Holdings, LLC**

By: VHCP Management, LLC,  
its Manager

By: /s/ David L. Stepp  
Name: David L. Stepp  
Title: Authorized Signatory

**VHCP Management, LLC**

By: /s/ David L. Stepp  
Name: David L. Stepp  
Title: Authorized Signatory

/s/ David L. Stepp, as attorney-in-fact

**Nimish Shah**

/s/ David L. Stepp, as attorney-in-fact

**Bong Koh**

**Venrock Healthcare Capital Partners II, L.P.**

By: VHCP Management II, LLC,  
its General Partner

By: /s/ David L. Stepp  
Name: David L. Stepp  
Title: Authorized Signatory

**VHCP Co-Investment Holdings II, LLC**

By: VHCP Management II, LLC,  
its Manager

By: /s/ David L. Stepp  
Name: David L. Stepp  
Title: Authorized Signatory

**VHCP Management II, LLC**

By: /s/ David L. Stepp

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form SC 13G/A

Name: David L. Stepp  
Title: Authorized Signatory



CUSIP No. 09058V103		
---------------------	--	--

**EXHIBITS**

A: Joint Filing Agreement

B: Power of Attorney for Bong Koh (Incorporated by reference to Exhibit B to Schedule 13G filed on March 28, 2016)

C: Power of Attorney for Nimish Shah

**EXHIBIT A**

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of BioCryst Pharmaceuticals, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 13th day of February, 2017.

**Venrock Healthcare Capital Partners, L.P.**

By: VHCP Management, LLC  
Its: General Partner

By: /s/ David L. Stepp  
David L. Stepp  
Authorized Signatory

**VHCP Co-Investment Holdings, LLC**

By: VHCP Management, LLC  
Its: Manager

By: /s/ David L. Stepp  
David L. Stepp  
Authorized Signatory

**VHCP Management, LLC**

By: /s/ David L. Stepp  
David L. Stepp  
Authorized Signatory

**Venrock Healthcare Capital Partners II, L.P.**

By: VHCP Management II, LLC  
Its: General Partner

By: /s/ David L. Stepp

David L. Stepp  
Authorized Signatory

**VHCP Co-Investment Holdings II, LLC**

By: VHCP Management II, LLC  
Its: Manager

By: /s/ David L. Stepp  
David L. Stepp  
Authorized Signatory

---

**VHCP Management II, LLC**

/s/ David L. Stepp  
David L. Stepp  
Authorized Signatory

/s/ Bong Koh  
**BONG KOH**

/s/ Nimish Shah  
**NIMISH SHAH**

---

**EXHIBIT C**

**POWER OF ATTORNEY FOR SEC FILINGS**

The undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther, and Lisa D. Harris, signing individually, the undersigned's true and lawful attorney-in fact and agent to:

(i) prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the Exchange Act), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

(ii) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned's responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned's holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

IN WITNESS WHEREOF, the undersigned has cause this Power of Attorney to be executed as of this 13th day of February, 2017.

/s/ Nimish Shah

---